Payment overview · 2025
General Payments
$946.02
46 reported records · 15 companies
Healthcare provider profile · identity verified
Giuseppe Guaitoli, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BONITA SPRINGS, FL · NPI 1689620585
Verified facts
What the public records show
CMS Open Payments records show Giuseppe Guaitoli, M.D. received $946.02 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.52 | 17.5% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.84 | 14.6% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $114.22 | 12.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.88 | 9.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.93 | 7.9% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $74.73 | 7.9% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $71.34 | 7.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.44 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.78 | 4.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.49 | 2.8% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $23.94 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.08 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.74 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.60 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.49 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $946.02 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.84 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $114.22 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $74.93 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $74.73 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.82 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $73.82 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $71.34 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $61.44 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.03 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.03 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.61 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 876 | 276 |
| Atorvastatin Calcium | Atorvastatin Calcium | 825 | 272 |
| Levothyroxine Sodium | Levothyroxine Sodium | 565 | 170 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 515 | 173 |
| Lisinopril | Lisinopril | 475 | 151 |
| Losartan Potassium | Losartan Potassium | 437 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 142 |
| Hydrochlorothiazide | Hydrochlorothiazide | 329 | 107 |
| Metformin Hcl | Metformin Hcl | 293 | 101 |
| Simvastatin | Simvastatin | 283 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 272 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 83 |
| Omeprazole | Omeprazole | 218 | 78 |
| Alprazolam | Alprazolam | 216 | 72 |
| Jardiance | Empagliflozin | 177 | 56 |
| Allopurinol | Allopurinol | 176 | 58 |
| Gabapentin | Gabapentin | 175 | 65 |
| Ezetimibe | Ezetimibe | 168 | 60 |
| Trazodone Hcl | Trazodone Hcl | 158 | 56 |
| Eliquis | Apixaban | 156 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 45 |
| Glimepiride | Glimepiride | 131 | 43 |
| Furosemide | Furosemide | 129 | 51 |
| Sertraline Hcl | Sertraline Hcl | 129 | 46 |
| Carvedilol | Carvedilol | 123 | 42 |
| Mounjaro | Tirzepatide | 118 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 38 |
| Ozempic | Semaglutide | 111 | 29 |
| Metformin Hcl Er | Metformin Hcl | 110 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 30 |
| Montelukast Sodium | Montelukast Sodium | 96 | 33 |
| Spironolactone | Spironolactone | 91 | 31 |
| Finasteride | Finasteride | 87 | 30 |
| Meloxicam | Meloxicam | 84 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 30 |
| Valsartan | Valsartan | 77 | 28 |
| Potassium Chloride | Potassium Chloride | 76 | 31 |
| Famotidine | Famotidine | 74 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 24 |
| Azithromycin | Azithromycin | 66 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 27 |
| Lorazepam | Lorazepam | 66 | 20 |
| Tramadol Hcl | Tramadol Hcl | 63 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 18 |
| Azelastine Hcl | Azelastine Hcl | 60 | 23 |
| Ramipril | Ramipril | 60 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 49 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 20 |
| Atenolol | Atenolol | 57 | 19 |
| Clonazepam | Clonazepam | 53 | 12 |
| Celecoxib | Celecoxib | 52 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Entresto | Sacubitril/Valsartan | 49 | 13 |
| Methylprednisolone | Methylprednisolone | 48 | 40 |
| Lovastatin | Lovastatin | 47 | 15 |
| Prednisone | Prednisone | 45 | 19 |
| Warfarin Sodium | Warfarin Sodium | 45 | 18 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 16 |
| Trulicity | Dulaglutide | 44 | 13 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Torsemide | Torsemide | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Estradiol | Estradiol | 30 | 12 |
| Mirtazapine | Mirtazapine | 30 | 12 |
| Diazepam | Diazepam | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | 11 |
| Amoxicillin | Amoxicillin | 27 | 24 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Donepezil Hcl | Donepezil Hcl | 21 | 12 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $946.02 · 46 records | Novo Nordisk Inc | ABRYSVO, Attruby, Barostim Neo System, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENTRESTO, GARDASIL 9, IBSRELA, INSPIRE, Kerendia, LEQVIO, MOUNJARO, ONPATTRO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VAQTA, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error